| 20 July 2016 |
On 14 July 2016, the Committee for Medicinal Products for Veterinary Use (CVMP) recommended that the marketing authorisation for the centrally authorised medicinal product Velactis (cabergoline) be suspended temporarily. Velactis is used to reduce milk production in dairy cows at the time of drying off. The recommendation follows reports of serious adverse events after treatment with Velactis.
| 08 July 2016 |
Three projects will receive public funds of DKK 7 million, which the Danish Parliament has earmarked for research into possible adverse reactions from HPV vaccination.
| 05 July 2016 |
The June issue of Danish Pharmacovigilance Update.